Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Opat

Showing results (81-90 of 133) with videos related to

Pageof 14
Sort By:
Haematologica|September 25, 2025
Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry studyEliza Chung, Luke Wang, Cameron Wellard, et al.
Internal Medicine Journal|July 12, 2016
Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practiceM Alexander, R Blum, K Burbury, et al.
Leukemia & Lymphoma|February 20, 2024
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases RegistryDiva Baggio, Cameron Wellard, Eliza Chung, et al.
Blood|July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-upJudith Trotman, Stephen Opat, David Gottlieb, et al.
Internal Medicine Journal|August 25, 2016
Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy servicesM Alexander, R Beattie-Manning, R Blum, et al.
Internal Medicine Journal|July 8, 2024
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern eraDiva Baggio, Eliza Chung, Cameron Wellard, et al.
Blood Advances|September 9, 2025
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN studyRamón García-Sanz, Roger G Owen, Wojciech Jurczak, et al.
Blood Advances|December 3, 2024
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemiaBenjamin M Heyman, Stephen S Opat, Björn E Wahlin, et al.
The Lancet. Oncology|October 9, 2020
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trialFranck Morschhauser, Hervé Tilly, Aristeidis Chaidos, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2023
A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma RiskMichael K Odutola, Marina T van Leeuwen, Fiona Bruinsma, et al.
Pageof 14

Showing results (81-90 of 133) with videos related to

Sort By:
Pageof 14
Haematologica|September 25, 2025
Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry studyEliza Chung, Luke Wang, Cameron Wellard, et al.
Internal Medicine Journal|July 12, 2016
Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practiceM Alexander, R Blum, K Burbury, et al.
Leukemia & Lymphoma|February 20, 2024
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases RegistryDiva Baggio, Cameron Wellard, Eliza Chung, et al.
Blood|July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-upJudith Trotman, Stephen Opat, David Gottlieb, et al.
Internal Medicine Journal|August 25, 2016
Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy servicesM Alexander, R Beattie-Manning, R Blum, et al.
Internal Medicine Journal|July 8, 2024
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern eraDiva Baggio, Eliza Chung, Cameron Wellard, et al.
Blood Advances|September 9, 2025
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN studyRamón García-Sanz, Roger G Owen, Wojciech Jurczak, et al.
Blood Advances|December 3, 2024
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemiaBenjamin M Heyman, Stephen S Opat, Björn E Wahlin, et al.
The Lancet. Oncology|October 9, 2020
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trialFranck Morschhauser, Hervé Tilly, Aristeidis Chaidos, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2023
A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma RiskMichael K Odutola, Marina T van Leeuwen, Fiona Bruinsma, et al.
Pageof 14